Bioverativ: Just Stop The Bleeding

Biogen spinoff Bioverativ (NASDAQ:BIVV) will continue to gain hemophilia market share and is an attractive investment idea.

The prevalence of hemophilia A, which is due to hereditary factor VIII deficiency, has been estimated at more than 150,000 worldwide. Sales of all replacement therapies have been estimated at $10 billion. But so many products to choose from - see figure 1 below.

READ FULL ARTICLE HERE